RhumbLine Advisers
FBRX icon

RhumbLine Advisers’s Forte Biosciences FBRX Stock Holding History

RhumbLine Advisers’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-360
Closed -$303K – 3035
2021
Q2 		$303K Buy
+360
New +$324K ﹤0.01% 2783
2020
Q2 		– Sell
-71
Closed -$32K – 3076
2020
Q1 		$32K Hold
71
– – ﹤0.01% 2886
2019
Q4 		$14K Sell
71
-1
-1% -$227 ﹤0.01% 2942
2019
Q3 		$18K Hold
72
– – ﹤0.01% 2947
2019
Q2 		$181K Buy
72
+4
+6% +$11.9K ﹤0.01% 2813
2019
Q1 		$277K Buy
68
+6
+10% +$23.2K ﹤0.01% 2584
2018
Q4 		$191K Buy
62
+21
+51% +$90.4K ﹤0.01% 2749
2018
Q3 		$241K Sell
41
-3
-7% -$11.4K ﹤0.01% 2631
2018
Q2 		$154K Buy
44
+4
+10% +$14.6K ﹤0.01% 2797
2018
Q1 		$178K Buy
+40
New +$185K ﹤0.01% 2635

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

RhumbLine Advisers's FBRX Position: Q3 2021 in Review

RhumbLine Advisers sold out of Forte Biosciences (FBRX) in Q3 2021, closing a stake of 360 shares — an estimated $303K sold.

RhumbLine Advisers first reported a position in FBRX in Q1 2018 and held it in 10 quarters. The position peaked at $303K in Q2 2021. 57 funds tracked by Wall St. Rank hold FBRX as of Q3 2021.

  • RhumbLine Advisers reported no remaining Forte Biosciences position as of Q3 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 360 Forte Biosciences shares in Q3 2021, an estimated $303K.
  • RhumbLine Advisers first reported a position in Forte Biosciences in Q1 2018 and held it in 10 quarters.
  • RhumbLine Advisers's Forte Biosciences position peaked at $303K in Q2 2021.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2021.

Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.